Clinical trials
Locally Advanced Breast Cancer clinical trials
Below are recruiting locally advanced breast cancer clinical trials, each written for real people, not researchers. We’re tracking 728 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06154538RecruitingPhase 2
Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Denver, ColoradoAges 18 years+ - NCT06107686RecruitingPhase 2
YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hefei, AnhuiAges 18–75 - NCT06123988Recruiting
Fasting and exercise for advanced breast cancer
This study looks at whether fasting overnight and/or doing exercise can help improve fatigue and other quality-of-life measures in women with advanced hormone receptor positive breast cancer who are already taking a CDK4/6 inhibitor. Participation may involve following a fasting or exercise plan for a period of time.
Phoenix, ArizonaAges 18 years+ - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06085742RecruitingPhase 2
CMC chemotherapy for early stage breast cancer
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
Chicago, IllinoisAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Birmingham, AlabamaAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03694756Recruiting
Testing special MRI to see tiny breast cancer structures
This study is testing whether a special MRI scan can help show tiny features inside breast tumors (TMEM). It’s mainly a “feasibility” study, meaning the team is checking if the scan can be done safely and clearly in different types of operable breast cancer.
The Bronx, New YorkAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT05982093RecruitingPhase 2
Elacestrant with or without triptorelin for premenopausal breast cancer
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Badalona, BarcelonaAges 35 years+ - NCT05933395RecruitingPhase 2
Targeted treatment for ER+ breast cancer after CDK4/6 therapy
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
Lebanon, New HampshireAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05806060RecruitingPhase 3
Targeted first treatment for a rare TNBC subtype with spread
This Phase 3 trial tests a more precise treatment strategy for a specific rare type of triple-negative breast cancer (TNBC) called the BLIS subtype. It’s for people whose cancer has spread or cannot be fully removed and who have not had chemo or targeted therapy for metastatic TNBC yet.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130
Hear when a new Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced breast cancer?
- Yes. Clin2 currently lists 728 recruiting locally advanced breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Advanced Breast Cancer
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced Pancreatic Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.